Lifestyle changes plus probiotic use were linked with better HbA1c in one man with type 2 diabetes
Key takeaway:
In one man with long-standing type 2 diabetes, a combined non-drug plan including lifestyle changes and probiotic supplementation was associated with lower HbA1c, lower triglycerides, and improved body composition over 3 to 6 months.
Study at a glance
What was studied
A bundled non-drug metabolic plan with probiotic and lifestyle change in one man with type 2 diabetes.
Study type
non-randomized clinical trial (non-RCT or NRCT)
duration
Medium-Term (3–12 mo)
Intervention
Probiotics, Behavioral counseling
Outcomes
HbA1c, Triglycerides, Body weight, Body fat mass, Treatment adherence
Funding
Industry sponsored
Main effects
↓ HbA1c decreased from 7.2% to 5.9% at 3 months
↓ Triglycerides decreased from 667 mg/dL to 113 mg/dL at 3 months
↓ Body fat mass and body weight decreased over 6 months
Evidence Suggest
- A combined lifestyle-plus-probiotic strategy may support short-term metabolic improvement in selected individuals
- Body composition can improve alongside glycemic markers in comprehensive non-drug plans
- Single-case evidence is hypothesis-generating and cannot establish causality
Who this applies to
Adults with type 2 diabetes who are motivated for intensive lifestyle change
Keep in Mind
This is low-certainty evidence from one person
Between the Lines
- Single-patient case report without control group
- Multiple interventions started together, including testosterone therapy
- Potential sponsor and conflict-of-interest bias
- Several outcomes were not reassessed at 6 months
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Journal Reference
Griffith A, Perlman A, Karr T, Thompson ME, Kolterman O. Case Report: Lifestyle changes and probiotic supplementation for improving longstanding type 2 diabetes in a male undergoing testosterone replacement therapy. Front Endocrinol (Lausanne). 2025;16:1754430. doi:10.3389/fendo.2025.1754430
Sources
Ranked by clinical relevance and evidence quality.
Key References
Most relevant evidence and guidance related to this research.
FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes | American Association of Clinical Endocrinology
Abaloparatide Followed by Alendronate Shows Promising Results for Women With Osteoporosis, T2D | American Association of Clinical Endocrinology
Supporting Evidence
Supporting evidence and related resources.
Connecting the Dots: Diabetes, CKD, and CVD Pathways | American Association of Clinical Endocrinology
Linagliptin Does Not Increase Adverse Renal Events in Patients With T2D, Kidney Disease | American Association of Clinical Endocrinology
Episode 39: AACE 2023 Updated Comprehensive Type 2 Diabetes Management Algorithm | American Association of Clinical Endocrinology
NIDDK: Type 2 Diabetes
Mayo Clinic: Type 2 diabetes diagnosis and treatment
Gut Microbiota Modulation in Type 2 Diabetes and Cardiometabolic Risk: A Systematic Review.
13 total sources in this category
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.